ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir Announces First Patient Enrolled…

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody

ExeVir announces first subjects dosed…

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir and Mithra announce manufacturing…

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir’s COVID-19 antibody candidate neutralizes…

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

ExeVir Announces Close of US$50…

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

ExeVir Bio Announces New Publication…

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir Bio Appoints Michel Kazatchkine…